Production (Stage)
Axsome Therapeutics, Inc.
AXSM
$102.99
-$0.99-0.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.27% | 13.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.27% | 13.37% | |||
| Cost of Revenue | -6.90% | 24.62% | |||
| Gross Profit | 3.16% | 12.38% | |||
| SG&A Expenses | 6.64% | 18.53% | |||
| Depreciation & Amortization | -2.18% | 0.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.92% | 19.47% | |||
| Operating Income | 10.00% | -33.31% | |||
| Income Before Tax | 20.60% | -15.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.69% | -15.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.69% | -15.96% | |||
| EBIT | 10.00% | -33.31% | |||
| EBITDA | 10.45% | -34.83% | |||
| EPS Basic | 21.22% | -15.00% | |||
| Normalized Basic EPS | 9.91% | -31.33% | |||
| EPS Diluted | 20.94% | -15.00% | |||
| Normalized Diluted EPS | 9.91% | -31.33% | |||
| Average Basic Shares Outstanding | 0.68% | 0.83% | |||
| Average Diluted Shares Outstanding | 0.68% | 0.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||